| Document |
Document Title |
|
WO/2007/051355A1 |
A DNA sequence is for a recombinant D-amino acid oxidase with catalytic activity on cephalosporin C that is not less than 25% higher than that of its parent.
|
|
WO/2007/053724A2 |
The present invention encompasses the solid state chemistry of cefdinir potassium salt.
|
|
WO/2007/042917A1 |
The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of crystalline Ceftiofur sodium of formula (I).
|
|
WO/2007/013043A2 |
The invention relates to processes for the preparation of 7-amino-3-vinyl cephalosporanic acid. The invention also relates to a crystalline form of 7-amino-3-vinyl cephalosporanic acid and process for its preparation.
|
|
WO/2007/008672A1 |
A novel crystalline cefdinir trihemihydrate , ways to make it and use it, compositions comprising it and made with it, and methods of treatment using it are disclosed.
|
|
WO/2007/008673A2 |
A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed.
|
|
WO/2007/008674A1 |
Crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed.
|
|
WO/2007/001804A1 |
A new and useful way of treating oxidized-contaminant-containing water, soil, rock, other geological or non-geological matrix formation (such as a landfill) is provided. A bioreactor is provided that includes elemental sulfur and a micro...
|
|
WO/2006/134607A1 |
The present invention provides an improved process for the preparation of high assayed cefdinir. Thus, crude cefdinir is added to water at 25 - 30°C and then 18% hydrochloric acid is slowly added to form a clear solution. The solution i...
|
|
WO/2006/117794A1 |
The present invention relates to a novel crystalline form of cefdinir, process for its preparation and to a pharmaceutical composition containing it. Thus, cefdinir is added to water at 20 - 25 °C and then hydrochloric acid (18 %) is ad...
|
|
WO2006006040B1 |
The present invention relates to an improved process for the preparation of cephalosporin antibiotics of formula (I). The present invention also provides new salts of compound of formula (II) and a process for the preparation of these ne...
|
|
WO/2006/109324A2 |
The present invention provides processes for the preparation amorphous form of Cefepime acid addition salt in high purity which exhibits very good thermal stability on storage. The processes are simple and cost-effective. The selective s...
|
|
WO/2006/106529A1 |
Stable and sterile composition of cefepime and a process for preparing the same. Amorphous composition containing cefepime acid addition salt or solvates thereof and organic or inorganic base obtained by spray drying of their aqueous sol...
|
|
WO/2006/104141A1 |
A compound represented by the formula: (I) wherein Acyl represents an acyl group which can be used in the field of β-lactams; T represents S, SO or O; the group represented by the formula: (Q) represents a heterocyclic group which may b...
|
|
WO/2006/103686A1 |
There is provided an improved process for preparing cefixime. Thus, for example, 7-amino-3-vinyl-3-cephem-4-carboxylic acid is reacted with 2-mercapto-1,3-benzothiazolyl-(Z)-2-(2-aminothiazol-4-yl)-2-
(methoxycarbonyl)-methoxyimino aceta...
|
|
WO/2006/100574A1 |
The present invention relates to amorphous cefditoren pivoxil granules having improved solubility, absorption and wetting characteristics with a reduced bitter taste, and processes for the preparation thereof.
|
|
WO/2006/085978A2 |
Fluorescent substrates for beta-lactamases having the general formula shown above are provided. Z includes a fluorophore or chromophore and includes a group that may link to the lactam-containing group; R1 and R2 are independently select...
|
|
WO/2006/080484A1 |
A process for producing cefcapene pivoxil methanesulfonate and, with the use thereof as an intermediate, corresponding hydrochloride. There is provided methanesulfonate of the compound of the formula (&Igr ).
|
|
WO/2006/075244A2 |
The present invention relates to a process for the production of cephalosporin antibiotic intermediate of formula (I). More particularly relates to the preparation of the compound of formula (I) using a solvent medium selected from the g...
|
|
WO/2006/067803A1 |
A novel process is disclosed for preparation of cefepime, a cephalosporin antibiotic in two steps comprising of (i) acylation of 7-Amino-3-[(1-methyl-1-pyrrolidinium)methyl]-3-cephem-4-carb
oxylate hydrochloride (IV) with 4-bromo-2-metho...
|
|
WO/2006/067806A1 |
The present invention provides an improved process for the preparation of Cefixime of formula (I), a cephalosporine antibiotic with an improved quality in regard to color and solubility.
|
|
WO/2006/059753A1 |
The present invention relates to a novel oral pharmaceutical suspension of cefdinir crystal. More specifically, the present invention relates to a novel kit for preparation of an oral pharmaceutical suspension containing crystal form C C...
|
|
WO/2006/053625A1 |
The invention relates to crystalline Cefdinir ammonium salt of formula (I).
|
|
WO/2006/048887A1 |
The present invention relates to a process for preparing a key intermediate of cefprozil and use of this intermediate in the preparation of cefprozil thereby avoiding impurity-causing self-acylation. [R-(Z)]-[4-hydroxy-&agr -[(3-methoxy-...
|
|
WO/2006/035291A1 |
The present invention relates to a novel crystalline potassium salt of cefdinir - cefdinir potassium tetrahydrate, processes for its preparation, pharmaceutical compositions including cefdinir potassium tetrahydrate, and methods of treat...
|
|
WO/2006/024741A2 |
The invention concerns an aminoquinoline-antibiotic hybrid compound of general formula (I): Q-(Y1)p-(U)p'-(Y2)p''-A; wherein Q represents an aminoquinoline, (Y1)p-(U)p'-(Y2)p'' is an optional spacer and A is an antibiotic residue. The in...
|
|
WO/2006/024900A1 |
The present invention relates to a highly pure cefditoren pivoxil having purity above about 98.5% and total impurity content less than about 3.0% when measured by HPLC.
|
|
WO/2006/018807A1 |
The invention relates to processes for the preparation of crystalline polymorphic forms of cefdinir of formula I. More particularly, it relates to the preparation of crystalline polymorphic forms of cefdinir designated as Forms B and C. ...
|
|
WO/2006/010978A1 |
A new crystalline Syn-7-[2-(2-amino-4-thiazolyl)-hydroxyiminoacetamido]-3-viny
l-3Âcephem-4-carboxylic acid-imidazole salt and polymorphic forms C, D and amorphous form of Syn-7-[2-(2-amino-4-thiazolyl)hydroxyimino-acetamido]-3-viny
l-3...
|
|
WO/2006/008161A1 |
Subject of the present invention are N,N-dimethyl alkanoyl amide solvates of 2-(2-aminothiazole -4-yl)-2(acyloxyimino)acetic acid compounds of formula (I) which may be prepared in an anhydrous form. Crystalline compounds of formula I are...
|
|
WO/2006/008749A1 |
The present invention relates to a process for preparing key intermediates for cephalosporin antibiotics substantially free of undesired delta A2 isomer. Thus, 7-aminocephalosporanic acid (7-ACA) is silylated with hexamethyldisilazane in...
|
|
WO/2005/121154A1 |
Provided are intermediates for use in synthesis of Cefdinir and processes for preparing cefdinir with such intermediates.
|
|
WO/2005/118595A1 |
A process for the production of 7-amino-3-[(E/Z)-2- (4-methylthiazol-5-yl)vinyl]-3-cephem-4-carboxylic acid of formula (1) and alkali metal salts thereof which have enhanced contents of 7-amino-3-[(Z)-2-(4-methylthiazol-5-yl)vinyl]-3- ce...
|
|
WO/2005/118596A1 |
3-Alkenylcephem compounds represented by the general formula (1): wherein R1 is benzyl or phenoxymethyl; R2, R3 and R4 are each independently hydrogen, C1-10 alkyl, C4-8 cycloalkyl, or aryl C1-3 alkyl whose aryl moiety may be substituted...
|
|
WO/2005/112648A1 |
The present invention relates to sulphur-containing oils, their preparation, and their use in controlling/killing plant pathogens and stimulating a plant’s uptake of essential elements from the soil and to act as a soil pH adjuster.
|
|
WO/2005/105813A1 |
A process for the production of (6R,7R)-7-[2-(2-Amino-4-thiazolyl)-2-synÂmethoxyimino)aceta
mido]-3-[[2,5-dihydro-6-hydroxy-2-methyl-5-oxo-as-triazin-3Â
yl)thio]methyl]-8-oxo-5-thia-l-azabicyclo[4.2.0]-oct-2-ene-
2-carboxylic acid (Cef...
|
|
WO/2005/100367A1 |
The present invention relates to crystalline intermediates useful in the synthesis of 3-(2-substituted vinyl) cephalosporins and processes for their preparation. In particular, the present invention relates to crystalline ylides of Formu...
|
|
WO/2005/100330A1 |
The present invention relates to the preparation of 4-methylthiazol-5-carboxaldehyde of Formula I, and use thereof as an intermediate in preparation of 3-[2-(4-methylthiazole-5-yl)vinyl] cephalosporins.
|
|
WO/2005/100368A2 |
The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-
3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorph...
|
|
WO/2005/100369A1 |
The present invention relates to depleting E-isomers of 3-(2-substituted vinyl) cephalosporins from a Z/E mixture of the same by selective crystallization techniques. The present invention to Z-enriched compounds comprising less than 5 %...
|
|
WO/2005/094800A2 |
The present invention provides a stable and sterile composition of Cefepime with a pharmaceutically acceptable non-toxic organic and inorganic base in high purity which exhibits good thermal stability which is obtained by co precipitatio...
|
|
WO/2005/092900A1 |
This invention relates a process for preparing a compound of formula (I), wherein R1 is para-nitrobenzyl or allyl; X is halo; as well as its isomers.
|
|
WO/2005/090361A1 |
The present invention relates to trihemihydrate, novel lower hydrate and anhydrate forms of 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-
3-cephem-4-carboxylic acid (syn isomer), methods for their preparation, and pharmace...
|
|
WO/2005/090360A1 |
The present invention relates to novel polymorph of cefdinir represented by formula (I). More particularly, the present invention relates to novel crystalline form (Crystal D) of cefdinir. The present invention also provides a process fo...
|
|
WO/2005/085258A1 |
A compound represented by the formula [Chemical formula 1] (I) &lcub wherein A is optionally substituted lower alkylene [substituent: mono- or di(lower alkyl), lower alkylidene, or C2 or higher (lower alkylene)]; and Z+ is either of the ...
|
|
WO/2005/076694A2 |
A process for the production of 7-[2-(2-amino-4-thiazolyl)-2-syn-methoxyimino-acetamido]-3-a
cetoxymethyl-3-cephem-4-carboxylic acid (Cefotaxime) in aqueous isopropyl alcohol is discussed. The synthesis is effected by condensing 7-aminoc...
|
|
WO/2005/071096A2 |
The present invention relates to compounds which are derivative of cephalosporin and for clavulanic acid that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable ...
|
|
WO/2005/063772A1 |
The invention relates to a new process for the production of intermediates for the synthesis of cephalosporin of formula (I) wherein R1, R2 and R3, independently of one another, are aklyl, alkenyl, aryl, hydroxy(C1-6)alkyl, carbamoyl-(C1...
|
|
WO/2005/051959A1 |
The present invention discloses the ß-lactamase-resistant cephalosporin ester compounds represneted by the following formula (I), characterized in that the structures of the compounds are composed by connecting methly ester residue of s...
|
|
WO/2005/044824A2 |
The present invention relates to a process for preparation of highly pure amorphous and crystalline forms of cefditoren pivoxil and pharmaceutical compositions comprising highly pure amorphous and crystalline forms of cefditoren pivoxil....
|
